Life Science Investor Mandates
(Jan. 17 - Jan. 23
)
|
|
|
|
|
Seeks Opportunities in Early to Commercial Stage Devices, Diagnostics, and Digital Health
|
|
Seeks to Invest Up to $10M in Digital Health Technologies Through Its CVC Arm
|
|
Invests Up to $30M in Venture to Growth-Stage Life Science Companies with Strong Interest in Orphan Diseases, Oncology, etc.
|
|
Seeks Digital Health Investment Globally, Especially in Telemedicine and AI-Based Data Processing
|
|
|
By Karen Deyo, Investor Research Analyst, LSN
 With RESI SF behind us, we are looking forward to LSN's first RESI in Europe. Taking place in Vienna, the inaugural RESI Europe will occur on March 25th at the Vienna Marriott Hotel. The application portal is now open for the RESI Europe Innovation Challenge. For RESI San Francisco, LSN received over a hundred applications from startups featuring their new technologies, and we are excited to review your applications for RESI Europe.
Companies can apply through the online portal, with supplementary materials sent to RESI@lifesciencenation.com. The submission deadline is February 20th, 2019.
We will select the top 30 companies as finalists, giving them the opportunity to display a poster featuring their technology in the exhibit hall for the entire day...
|
 |
 |
By Lucy Parkinson, VP of Investor Research, LSN
 RESI's first Europe event will include three tracks of panel and workshop content aimed at educating entrepreneurs on key topics in life science capital raising. RESI's panels all feature experienced investors who can provide real-world insights to entrepreneurs and reveal their decision-making process and what catches their eye in a deal.
RESI Europe's agenda includes our first ever panel on the Greater European Early-Stage Ecosystem, and a new combined look at Angels and Seed Funds to provide entrepreneurs with actionable insights for their first capital raise. Popular special topic panels return, including AI in Healthcare and Microbiome, and two panels are focused on how to source investors from the Asia region - Asia Therapeutic Investors and Asia Corporates & Strategics. Additionally, RESI Europe features panels on every major life science vertical and on some key investor types such as Family Offices and Corporate Venture Capital. If you'd like to attend these panels live, register for RESI Europe now...
|
|
|
By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN
 Taiwan has been an important player and a pioneer in the world's IT industry. Nowadays, through government support, Taiwan is also trying to establish its presence in life science industry, particularly in the Medical Device sector.
At RESI San Francisco during JPM week, LSN and BioMed TW cooperated to launch a new Taiwan Investor panel. The main purpose of this panel is to inform international startups' on why Taiwan matters. We had the pleasure of inviting 6 panelists from Taiwan - all with a unique background related to Taiwan and working with early-stage innovations - to speak about their work and their perspectives on why international startups should approach Taiwan investors.
Our panelists included:
- Michel Chu, General Partner, Acorn Campus Taiwan (Moderator)
- Shaoyu Chang, Vice President, FC Capital
- IC Jan, Director of Corporate Development, Taiwania Capital
- Yi-Yen Chen, Investment Professional, WI Harper Group
- Yuh-Geng Tsay, Venture Partner, Vivo Capital
- William Tai, Managing Partner, Amed Ventures
|
|
|
|
|
|
|
Created & Produced by
|
 |
|
|
|
